Poor clinical outcomes for hemodialysis (HD) patients compared to non-HD patients after coronary intervention have been reported. Although coronary intervention using sirolimus-eluting stents (SESs) might be expected to reduce restenosis in HD patients, little is known about the efficacy of the SESs. The purpose of the present study was to compare the clinical and angiographic outcomes of HD patients with non-HD patients after SES implantation. The study population consisted of 170 consecutive patients (234 lesions) who had undergone successful coronary SES implantation. The patients were classified into 2 groups, an HD group (18 patients, 27 lesions) and a non-HD group (152 patients, 207 lesions). The incidence of any clinical event was significantly higher in the HD group than in the non-HD group (50.0% versus 12.5%, P < 0.0001). Target lesion revascularization was necessary in 6 patients (33.3%) in the HD group and in 7 patients (4.6%) in the non-HD group (P < 0.0001). The Cox proportional-hazards regression model on cardiac events identified HD patients (P = 0.0301, hazard ratio = 2.704) as an explanatory factor. Moreover, the Cox proportional-hazards regression model on target lesion revascularization identified HD (P = 0.0004, hazard ratio = 6.921) and in-stent restenosis lesion (P = 0.0293, hazard ratio = 3.323) as explanatory factors. The present study suggests that compared with non-HD patients, HD patients with coronary artery disease treated by SESs have a poorer clinical outcome. (Int Heart J 2007; 48: 689-700) Key words: Sirolimus-eluting stents, Hemodialysis, Clinical outcome HEMODIALYSIS (HD) patients are well known to be a high risk population for coronary artery disease. 1) Moreover, poor clinical outcomes compared to non-HD patients after coronary intervention have been reported. 2,3) Previous studies of sirolimus-eluting stents (SESs) compared with bare-metal stents (BMSs) in coronary artery disease have demonstrated a reduction in the incidence of cardiac events related to recurrent ischemia and lower rates of angiographic restenosis.
Although coronary intervention using SESs might be expected to reduce coronary restenosis in HD patients with coronary artery disease, little is known about the efficacy of the SESs. The purpose of the present study therefore was to compare the clinical and angiographic outcomes of HD patients with non-HD patients after SES implantation. . HD patients were defined as having been treated with HD for at least 90 days prior to the catheter intervention. All the enrolled patients gave written informed consent, and the study protocol was based on the regulations of the hospital's ethics committee.
METHODS
The clinical characteristics, which included age, gender, coronary risk factors (hypertension, hypercholesterolemia, diabetes mellitus, smoking habit), clinical presentation, prior myocardial infarction and/or catheter intervention and/or coronary artery bypass graft surgery are shown in Table I . Patients were defined as hypertensive if diastolic blood pressure was at least 90 mmHg and/or systolic blood pressure was at least 140 mmHg or if they were taking antihypertensive medication. Patients whose serum total cholesterol concentration was at least 220 mg/dL or who were taking antihypercholesterolemic medication were defined as having hypercholesterolemia. Patients whose fasting glucose concentration was at least 126 mg/dL and/or hemoglobin A1c at least 6.5% before drug or dietary treatment for at least 1 year prior to the present study or who were taking antidiabetic medication were defined as diabetic. Because a 75 g oral glucose tolerance test was not performed in all of the patients, diabetes mellitus was only diagnosed based on the fasting glucose concentration and hemoglobin A1c level. Coronary stenting and quantitative coronary angiography: The angiographic characteristics of all subjects are also summarized in Table I . Conventional balloon angioplasty was the only procedure carried out in all patients before stent implantation. Balloon or stent size and pressure were left to the discretion of the operator. Multiple stents were deployed if necessary to cover the full extent of the target lesion, or the dissection if it occurred. Procedural success was defined as successful deployment of the stent and residual stenosis less than 30% on quantitative coronary angiography. After stent implantation, adjunctive postdilation was performed using a high pressure balloon to achieve a residual stenosis less Vol 48 No 6 than 30%. All patients received intravenous heparin (100 IU/kg) during the procedure and all received antiplatelet therapy (aspirin 100 mg/day, and ticlopidine 200 mg/day or cilostazol 200 mg/day). Lifelong aspirin administration was recommended in all patients, and ticlopidine or cilostazol was continued for at least 6 months after the procedure. Quantitative coronary angiography was performed using a SIEMENS DCI-ACA imaging system. The contrast-filled guiding catheter was used as a reference. Intracoronary isosorbide dinitrate (3 mg) was administered before all angiographic assessments. The diameters of the normal segments proximal and distal to the treated area were averaged to determine the reference diameter. The minimum lumen diameter and the percentage of diameter stenosis after coronary stenting were calculated by single-plane, worst-view angulation. Lesions requiring coronary stenting were characterized according to the modified ACC/AHA characteristics. 8, 9) The severity of calcification of the target lesion on coronary angiography in HD patients was semiquantitatively scored according to the 3 grade scoring system described by Tsuchihashi, et al 10) which is as follows: 3, the same density as bone; 2, clear calcification not as dense as healthy bone; and 1, fair calcification. Clinical and angiographic follow-up: All patients had follow-up coronary angiography at 6 to 9 months after coronary intervention, and all patients were 
Values are n (%). HD indicates hemodialysis and NS, not significant. followed more than 12 months after SES implantation. Target lesion revascularization was indicated by the presence of clinical or functional ischemia and more than 75% diameter stenosis or a restenosed lesion more than 90% in the absence of documented ischemia. Clinical events were defined as death, congestive heart failure, nonfatal myocardial infarction, coronary artery bypass graft surgery, repeat coronary intervention of the target lesion, and nonstented lesions (new lesion). Coronary intervention of a new lesion was also indicated by the presence of clinical or functional ischemia and more than 75% diameter stenosis or more than 90% in the absence of documented ischemia. Cardiac events were defined as clinical events without noncardiac death. In-hospital events were included in the analysis of follow-up events. Statistical analysis: All data are expressed as the mean ± SD or n (%). The difference in mean values between the 2 groups was compared using an unpaired t test. The incidences in the 2 groups were compared using the chi-square test. A repeat revascularization curve was created by the Kaplan-Meier method to determine the time-dependent cumulative repeat revascularization free rate and compared using log rank tests. The Cox proportional-hazards model was used to determine independent predictors of cardiac events and target lesion revascularization. To determine independent explanatory factors correlated with cardiac events, we included age (≥ 70 years), coronary risk factors (presence or absence), HD or non-HD, prior myocardial infarction, prior catheter intervention, prior coronary artery bypass graft surgery, multivessel or not multivessel, multivessel catheter intervention, and clinical presentation (acute myocardial infarction or not) as factors in the analysis. To determine independent explanatory factors correlated with target lesion revascularization, we included coronary risk factors (presence or absence), HD or non-HD, ACC/AHA lesion type (type C or not), in-stent restenotic lesion or not, lesion length (≤ 25 mm or > 25 mm), stented length (≤ 35 mm or > 35 mm), reference diameter (< 3.0 mm or ≥ 3.0 mm), and percent diameter stenosis (≤ 15% or >15%) as factors in the analysis. Statistic analysis was performed with an SPSS Advanced Statistics 10.0 package (SPSS Japan, Inc., Japan). A P value less than 0.05 was considered significant. Table I presents the clinical and angiographic characteristics of the two groups. There were no significant differences between them in terms of age, gender, coronary risk factors, prior myocardial infarction, prior catheter intervention, prior coronary artery bypass graft surgery, and clinical presentation. However, the HD group had a significantly higher incidence of multivessel disease than that of the non-HD group. There were also no significant differences between them in terms of site of intervention, reference diameter, minimum lumen diameter, and percent diameter stenosis as determined by postprocedural quantitative coronary angiography, but the HD group had a significantly higher incidence of ACC/AHA lesion type C and calcification than those of the non-HD group. The HD group had significantly longer lesion and stented lengths.
RESULTS

Clinical and angiographic characteristics:
Clinical events: Table II shows the hard clinical events of the two groups. No significant differences in hard events (death, nonfatal myocardial infarction, and stent thrombosis) were found between in the HD and the non-HD groups. The Figure shows Kaplan-Meier free from repeat revascularization (due to target lesion revascularization and/or new lesion) curves of all coronary lesions in the HD and non-HD groups. The occurrence of repeat revascularization was higher in the HD group than in the non-HD group (P < 0.0001). Target lesion revascularization was necessary in 6 patients (33.3%) in the HD group and in 7 patients (4.6%) in the non-HD group, and repeat revascularization due to a new lesion was necessary in 1 patient (5.6%) in the HD group and in 10 patients (6.6%) in the non-HD group. Predictors of cardiac events and target lesion revascularization: Table III shows a comparison of the patient group with and without cardiac events. Three patients (5 lesions) died of a noncardiac cause (1 lung carcinoma, 2 pneumonia) without cardiac events. These patients were excluded from further cardiac event and tar- get lesion revascularization analysis. The cardiac event group had a greater incidence of HD patients (P < 0.0001) and patients who had undergone multivessel catheter intervention (P = 0.008) compared to the no cardiac event group. Table  IV shows a comparison of the coronary lesion group with and without target lesion revascularization. The target lesion revascularization group also had a greater incidence of HD (P < 0.0001), in-stent restenosis lesion (P = 0.022), and had significantly longer lesion (P = 0.014) and stented lengths (P = 0.024) com- pared to the no target lesion revascularization group. The Cox proportional-hazards regression model on cardiac events identified HD patients (P = 0.0301, hazard ratio = 2.704) as an explanatory factor (Table V) . Moreover, the Cox proportional-hazards regression model on target lesion revascularization also identified HD (P = 0.0004, hazard ratio = 6.921) and in-stent restenosis lesion (P = 0.0293, hazard ratio = 3.323) as explanatory factors (Table V) .
Comparison with and without target lesion revascularization in HD patients:
Table VI presents a comparison of the clinical and angiographic parameters between lesions with and without target lesion revascularization in HD patients. The target lesion revascularization group had a greater incidence of diabetes mellitus (P = 0.034) and had a higher calcification score of the target lesion (P = 0.002) compared to the no target lesion revascularization group.
DISCUSSION
The findings of the present study suggest that compared with non-HD patients, HD patients with coronary artery disease treated by SESs results in a poor clinical outcome. Percutaneous catheter intervention in HD patients: Previous studies have dem- Values are shown as mean ± SD or n (%). NS indicates not significant; PCI, percutaneous catheter intervention; QCA, quantitative coronary angiography; and TLR, target lesion revascularization.
Vol 48 No 6 onstrated that BMS implantation, compared with balloon angioplasty without stents, reduced the incidence of major adverse cardiac events in HD patients. 11) However, clinical outcome after coronary intervention of patients with HD remains poor in comparison with the non-HD population in the BMS era.
2,3) SES implantation has been proven to markedly reduce the incidence of angiographic restenosis and repeat revascularization in patients with coronary artery disease. The RAVEL and SIRIUS trials demonstrated the safety and efficacy of SESs in selected patients, compared to BMSs, including long-term clinical outcome. [4] [5] [6] The RESEARCH registry also reported SES implantation was associated with a reduction in the rates of repeat revascularization and cardiac events in a consecutive unselected cohort of patients.
12) However, only a few studies have evaluated the efficacy of SESs in HD patients. Thus, little is known about the efficacy of SESs in HD patients with coronary artery disease. In the present study, the clinical outcome of the non-HD group was comparable to that of previous studies. That is, in the non-HD group, the incidence of any clinical event was 12.5% and target lesion revascularization was only necessary in 7 patients (4.6%) during the follow-up period. Previous studies also demonstrated that major adverse cardiac events and target lesion revascularization rates after SES implantation in HD patients were higher than those of non-HD patients, regardless of the beneficial effect of SESs. 13, 14) In the present study, the incidences of any clinical event (50.0%) and target lesion revascularization (33.3%) in the HD group were significantly higher than those of the non-HD group. However, the incidence of target lesion revascularization after BMS implantation in HD patients was 56.3% in the BMS period (from January 2003 to August 2004) at Sapporo Social Insurance General Hospital. Thus, these findings suggest that clinical and angiographic outcomes in HD patients with coronary artery disease should be improved by SESimplantation compared to BMS implantation. On the other hand, a previous study demonstrated a lower rate of repeat revascularization in HD patients after catheter intervention with drug-eluting stents. 15) Possible reasons for this favorable result compared to the present study are as follows. First, the mortality rate was higher (18.4%) than that of the present study (5.6%). Second, the angiographic characteristics were different (lesion length was 18.6 ± 13.2 mm and the rate of ACC/ AHA lesion type B2/C was 68%) compared to the present study. Third, in the present study, all patients underwent follow-up coronary angiography, that is, clinical follow-up only versus clinical and angiographic follow-up might have caused the discrepancy in the rate of repeat revascularization. On the other hand, HD patients are a high risk population for repeat revascularization due to treatment of nonstented (new) lesions. However, in the present study, repeat revascularization due to new lesions was necessary in only 1 HD patient. A small number (18 patients) of patients might be one of the reasons for this.
Mortality rate of HD patients: Cardiovascular events, especially related to coronary artery disease, remain the leading cause of mortality among patients with HD. 1) Furthermore, HD patients are also well known to have a higher mortality rate than non-HD patients. 1, 16) However, only 1 patient died during follow-up in the present study. A previous study demonstrated that coronary intervention could improve the prognosis of HD patients compared to medical treatment only. 16) In the present study, all patients had undergone successful coronary SES implantation. Moreover, all patients underwent follow-up coronary angiography, and repeat revascularization if necessary. This might be one of the reasons for the low mortality rate in the present study. In addition, HD patients with coronary artery disease treated by SESs should undergo not only clinical follow-up, but also angiographic follow-up in order to prevent cardiac death.
Differences in clinical and angiographic parameters between lesions with and without target lesion revascularization in HD patients: In HD patients, the target lesion revascularization group had a greater incidence of diabetic nephropathy, and had a higher calcification score for the target lesion compared to the no target lesion revascularization group in the present study (Table VI) . A previous study demonstrated that the clinical outcome after coronary angioplasty of HD patients with diabetes was poor compared to HD patients without diabetes. 17) Although the number of lesions in the present study (25 lesions) was too small to warrant a meaningful discussion, an indication of HD (diabetic nephropathy) might be a predictor of target lesion revascularization after stent implantation in patients with HD even in the SES era. Severe calcification of the target lesion may also be a predictor of target lesion revascularization after SES implantation in patients with HD. Coronary stenosis lesions in HD patients are often calcified due to calcium-phosphate balance disorder. 18) Severe calcification of target lesions and/or the proximal segment of target lesions may cause the peeling off of polymer containing sirolimus from the stent surface. A previous study reported that rotational atherectomy prior to coronary BMS implantation reduced the restenosis rate of the severely calcified coronary lesions. 11) In the present study, if predilatation was possible with a balloon, we implanted SESs even in severely calcified lesions without prior rotational atherectomy. However, the results of the present study suggest that rotational atherectomy prior to coronary SES implantation may improve the clinical and angiographic outcome in HD patients with coronary artery disease, especially in patients with severely calcified coronary lesions. Other predictive factors of target lesion revascularization: Recently, the effectiveness of drug-eluting stents has been evaluated for treatment of in-stent restenosis in patients previously treated with BMSs. Drug-eluting stents have been reported to be superior to conventional treatment for in-stent restenosis, such as balloon angioplasty and vascular brachytherapy. [19] [20] [21] In the present study, there was a significantly higher incidence of target lesion revascularization in the instent restenosis lesions (15.4%) than in de novo lesions (4.2%) (P = 0.022). Although SESs are superior to conventional treatment for in-stent restenosis, instent restenosis lesions themselves may be inferior to de novo lesions even in the SES era.
Study limitations:
The present study has several limitations. The results from the 18 consecutive patients (27 lesions) in the HD group and 152 consecutive patients (207 lesions) in the non-HD group suggest the need for a larger patient population. Also, the present study was not designed as a prospective randomized trial. Further studies using a larger patient population are therefore needed to evaluate the efficacy of the SESs in patients with HD and to determine independent factors correlated with cardiac events and target lesion revascularization.
